Archives

Hyoscyamine Sulfate SL

Hyoscyamine Sulfate Sublingual Tablets, USP contain 0.125 mg hyoscyamine sulfate formulated for sublingual administration. However, the tablets may be chewed or taken orally. Hyoscyamine sulfate is one of the principal anticholinergic/antispasmodic components of belladonna alkaloids. The empirical formula is (CHNO)… Continue Reading →

Concept DHA

DESCRIPTION: Each capsule contains: Ferrous Fumarate (Elemental Iron) . . . . . . . . . . 17.5 mg PolysaccharideIronComplex(ElementalIron).. 17.5mg(Equivalent to about 35 mg of elemental iron) Vitamin C (from ProAscorb C‡)    .    .    .    .    .    .  … Continue Reading →

BiferaRx

BiferaRx™ is a prescription iron supplement. BiferaRx™ is a small oval, film-coated maroon tablet, with black core, debossed and bisected with “AP|85” on one side, and plain on the other. Each BiferaRx™ tablet contains:

FIRST BXN Mouthwash

Each FIRST- BXN Mouthwash Compounding Kit is comprised of 0.2 grams of diphenhydramine hydrochloride powder USP, 1.6 grams of lidocaine hydrochloride powder USP, and 1.6 grams of nystatin powder USP for oral use. FIRST- BXN Mouthwash Compounding Kit also contains… Continue Reading →

Integra Plus

DESCRIPTION: Each capsule contains: Ferrous Fumarate (anhydrous) ……191.1 mg Polysaccharide Iron Complex… 135.9 mg (Equivalent to about 125 mg of elemental iron) Vitamin C (from ProAscorb C‡)….210 mg Folic Acid …..1 mg Thiamine Mononitrate (B1)…5 mg Riboflavin (B2)….5 mg Niacin… Continue Reading →

Salsalate

Salsalate, is a nonsteroidal anti-inflammatory agent for oral administration. Chemically, salsalate (salicylsalicylic acid or 2-hydroxy-benzoic acid, 2- carboxyphenyl ester) is a dimer of salicylic acid; its structural formula is shown below. Each tablet, for oral administration contains 500 mg or… Continue Reading →

INATAL Ultra

INATAL Ultra is a white, dye free, oval oil-and-water-soluble multivitamin/multimineral tablet with calcium citrate and carbonyl iron. Each tablet contains: Vitamin A* . . . . . . . . . . . . . . . . . .… Continue Reading →